« Return to News | Awards & Advancement

ERT awarded over $10 Million in ePRO business

Thursday, April 14, 2011 11:59 AM

ERT, a provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, was awarded three new contracts with pharmaceutical companies, totalling over $10 million for its electronic patient reported outcomes (ePRO) business.

The first ePRO award is an agreement with a specialty division of a pharmaceutical company that has selected ERT to manage a suite of studies using ERT’s proprietary VIAPhone platform over the next three years.  The contract will be worth in excess of $7 million. The second award is part of a $3.0 million contract for which ERT will provide its VIAPen solution for a pivotal phase III program. The third award has been secured with a pharmaceutical company that will be using ERT’s VIAPhone Pain Diary for use in a phase III clinical trial, alongside its VIAPen solution for site assessments.

John Blakeley, chief commercial officer at ERT, comments: “The broad scope of our solutions and expertise ensures that we are able to offer clients unbiased, ‘true partnership’ advice that allows for an accurate and cost-effective trial. Sponsors are increasingly choosing ERT for our industry knowledge and expertise as well as secure and reliable service.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.